Cargando…

Interplay of neutrophils and type I interferons in the development of end-organ damage in SLE

Detalles Bibliográficos
Autor principal:	Kaplan, MJ
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467511/ http://dx.doi.org/10.1186/ar3968

Ejemplares similares

Aggregation of MAVS antiviral protein suggests a mechanism for increased type I interferon production in SLE
por: Shao, Wen-Hai, et al.
Publicado: (2014)

SLE risk alleles and cell development and activation
por: Kim, SJ, et al.
Publicado: (2012)

The role of DNA in the pathogenesis of SLE
por: Pisetsky, DS
Publicado: (2001)

Genetic analysis of the pentraxin genes in SLE
por: Russell, AI, et al.
Publicado: (2001)

Vasculitis and Systemic Lupus Erythematous (SLE)
por: Cortis, Elisabetta, et al.
Publicado: (2015)

SLE: insights from array-based proteomics
por: Wu, T, et al.
Publicado: (2012)

T lymphocytes of patients with SLE lack Stat4
por: Aringer, M, et al.
Publicado: (2001)

Clinical impact of biologic therapy in the treatment of SLE
por: Wallace, Daniel J
Publicado: (2013)

Neuropsychiatric events in SLE: determination of attribution and assessment of outcome
por: Hanly, JG
Publicado: (2012)

PROMISSE: progress in understanding pregnancy complications in patients with SLE
por: Salmon, JE
Publicado: (2012)

Signalling via T cell receptor (TCR) in patients with SLE
por: Cebecauer, M, et al.
Publicado: (2001)

New reporter cell clones to determine the biological activity of human type I interferons
por: Bürgi, Milagros, et al.
Publicado: (2011)

Cause and consequences of the activated type I interferon system in SLE
por: Eloranta, Maija-Leena, et al.
Publicado: (2016)

Mycophenolate mofetil prevents the development of a clinical relapse in SLE patients at risk: an open pilot study
por: Bijl, M, et al.
Publicado: (2002)

B cells at the adaptive-innate immune system interface in SLE
por: Anolik, JH, et al.
Publicado: (2012)

Regulatory natural autoantibodies suppress inflammation and SLE disease activity
por: Silverman, GJ, et al.
Publicado: (2012)

Nucleosome binding by serum amyloid P component from SLE patients
por: Heegaard, NHH, et al.
Publicado: (2001)

Elevated anti-serum amyloid P component (SAP) antibodies in SLE patients
por: Zandman-Goddard, G, et al.
Publicado: (2003)

Clinical and immunological effects of anti-TNF therapy in systemic lupus erythematosus (SLE)
por: Aringer, M, et al.
Publicado: (2003)

IRF5 expression profiling in SLE patients: new leads to a pathogenic signature?
por: Barnes, BJ, et al.
Publicado: (2012)

Comparison of different immunoassays detecting anti-chromatin autoantibodies in systemic lupus erythematosus (SLE)
por: Roux-Lombard, P, et al.
Publicado: (2002)

Immuno-serological profile of Systemic Erythemic Lupus (SLE) patients with neuropsychiatric manifestations (NP)
por: Stojanovich, L, et al.
Publicado: (2001)

Local interferon-β gene therapy ameliorates adjuvant arthritis in rats
por: Adriaansen, P, et al.
Publicado: (2004)

MicroRNA-3148 modulates differential gene expression of the SLE-associated TLR7 variant
por: Deng, Y, et al.
Publicado: (2012)

High score on PREDICTS is associated with 10-fold increased odds for the progression of subclinical atherosclerosis in SLE
por: McMahon, M, et al.
Publicado: (2012)

Validating the expression of miRNAs in healthy controls and SLE patients and to predict possible gene targets
por: Chugha, Amandeep, et al.
Publicado: (2015)

Spontaneous aggregation of the anti-viral MAVS protein in systemic lupus erythematosus: a possible cause of excessive type I interferon production
por: Cohen, PL, et al.
Publicado: (2012)

Sociodemographic characteristics of SLE patients in a large metropolitan area with a high Afro-Caribbean population
por: Cabas-Vargas, J, et al.
Publicado: (2012)

Characterization of RA33 (hnRNP-A2/B1)-autoreactive T cells in SLE-patients
por: Fritsch, R, et al.
Publicado: (2001)

The association of HLA-DR/DQ coding and QBP promoter allelic polymorphism with antiphospholipid antibody response in SLE
por: Logar, D, et al.
Publicado: (2002)

Autoantibodies to the TNF-α translational regulators TIA-1 and TIAR occur frequently in sera of patients with SLE and scleroderma
por: Jimenez-Boj, E, et al.
Publicado: (2002)

Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
por: Isenberg, David, et al.
Publicado: (2014)

IL-21/type I interferon interplay regulates neutrophil-dependent innate immune responses to Staphylococcus aureus
por: Spolski, Rosanne, et al.
Publicado: (2019)

Increased concentrations of procollagen type III peptide in the evolution of septic phenomenon. An indicator of organ damage and fibrinogenesis? (Preliminary data results)
por: Mavrommatis, A, et al.
Publicado: (2001)

Autoantibodies to hnRNP-A2 in SLE: identification of disease-specific linear epitopes and correlation with disease activity and clinical features
por: Schett, G, et al.
Publicado: (2003)

Dominance of hydrophobic reading frames in complementarity determining region 3 of variable heavy chain genes from a patient with untreated SLE
por: Yazdani-Biuki, B, et al.
Publicado: (2001)

The interplay of excitatory and inhibitory coupling modes is crucial for the regulation of neuronal electrical activities by L-type calcium channels
por: Geier, Petra, et al.
Publicado: (2010)

Interferon-alpha and angiogenic dysregulation in pregnant lupus patients destined for preeclampsia
por: Andrade, Danieli, et al.
Publicado: (2014)

Troponin I as expression of myocardial damage after major vascular surgery
por: Consales, G, et al.
Publicado: (2002)

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
por: Casey, Kerry A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9thej8pcbfkftv0fdpemqi82e9